At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
FATE Fate Therapeutics
Pre-Mkt 06-11 06:19:11 EDT
1.87
-0.03
-1.58%
盘前1.87
+0.00+0.02%
05:18 EDT
High2.02Low1.87Vol2.06M
Open1.93D1 Closing1.90Amplitude7.63%
Mkt Cap217.41MTradable Cap188.49MTotal Shares116.26M
T/O3.92MT/O Rate2.04%Tradable Shares100.80M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Piper Sandler Remains a Buy on Fate Therapeutics (FATE)
TIPRANKS  ·  06-09 19:18
Piper Sandler Remains a Buy on Fate Therapeutics (FATE)
Wall Street Analysts Are Bullish on Top Healthcare Picks
TIPRANKS  ·  06-08 18:30
Wall Street Analysts Are Bullish on Top Healthcare Picks
Fate Therapeutics Price Target Maintained With a $7.00/Share by HC Wainwright & Co.
Dow Jones  ·  06-08 18:30
Fate Therapeutics Price Target Maintained With a $7.00/Share by HC Wainwright & Co.
Analysts Offer Insights on Healthcare Companies: United Therapeutics (UTHR), Fate Therapeutics (FATE) and Edgewise Therapeutics (EWTX)
TIPRANKS  ·  06-06
Analysts Offer Insights on Healthcare Companies: United Therapeutics (UTHR), Fate Therapeutics (FATE) and Edgewise Therapeutics (EWTX)
Fate Therapeutics Advances Off-the-Shelf CAR-T Autoimmune Pipeline
TIPRANKS  ·  06-05
Fate Therapeutics Advances Off-the-Shelf CAR-T Autoimmune Pipeline
Gil Blum Reiterates Hold on Fate Therapeutics as Early FT819 Data Show Promise but Uncertain Durability
TIPRANKS  ·  06-05
Gil Blum Reiterates Hold on Fate Therapeutics as Early FT819 Data Show Promise but Uncertain Durability
Fate Therapeutics reports Phase 1 data for FT819 CAR-T in lupus with reduced conditioning regimen
Reuters  ·  06-04
Fate Therapeutics reports Phase 1 data for FT819 CAR-T in lupus with reduced conditioning regimen
Fate Therapeutics Showcases Data from FT819 and FT839 Programs at the European Congress of Rheumatology Annual Meeting
GlobeNewswire  ·  06-04
Fate Therapeutics Showcases Data from FT819 and FT839 Programs at the European Congress of Rheumatology Annual Meeting
Fate Therapeutics management to meet with Piper Sandler
TIPRANKS  ·  06-04
Fate Therapeutics management to meet with Piper Sandler
Fate Therapeutics grants 67,300 RSUs to two new hires under inducement plan
Reuters  ·  06-03
Fate Therapeutics grants 67,300 RSUs to two new hires under inducement plan
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(C)(4)
THOMSON REUTERS  ·  06-03
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(C)(4)
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire  ·  06-03
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Fate Therapeutics reports early Phase 1 FT836 data showing tumor shrinkage in KRAS wild-type metastatic colorectal cancer without conditioning chemo
Reuters  ·  06-01
Fate Therapeutics reports early Phase 1 FT836 data showing tumor shrinkage in KRAS wild-type metastatic colorectal cancer without conditioning chemo
Fate Therapeutics Showcases Clinical Data for FT836 at the American Society of Cancer Oncology Annual Meeting
GlobeNewswire  ·  06-01
Fate Therapeutics Showcases Clinical Data for FT836 at the American Society of Cancer Oncology Annual Meeting
Analysts Offer Insights on Healthcare Companies: Zevra Therapeutics (ZVRA), Fate Therapeutics (FATE) and Mirum Pharmaceuticals (MIRM)
TIPRANKS  ·  05-27
Analysts Offer Insights on Healthcare Companies: Zevra Therapeutics (ZVRA), Fate Therapeutics (FATE) and Mirum Pharmaceuticals (MIRM)
CTXR, AMT, JAZZ, CTMX, FATE Trending With Analysts
TIPRANKS  ·  05-23
CTXR, AMT, JAZZ, CTMX, FATE Trending With Analysts
Top Fate Therapeutics Insiders Quietly Unload Shares in Back‑to‑Back Moves
TIPRANKS  ·  05-22
Top Fate Therapeutics Insiders Quietly Unload Shares in Back‑to‑Back Moves
Fate Therapeutics Announces Presentations at 2026 Asco and Eular Annual Meetings Highlighting off-the-Shelf Car T-Cell Therapy Pipeline for Cancer and Autoimmune Diseases
THOMSON REUTERS  ·  05-21
Fate Therapeutics Announces Presentations at 2026 Asco and Eular Annual Meetings Highlighting off-the-Shelf Car T-Cell Therapy Pipeline for Cancer and Autoimmune Diseases
Fate Therapeutics Announces Presentations at 2026 ASCO and EULAR Annual Meetings Highlighting Off-the-Shelf CAR T-cell Therapy Pipeline for Cancer and Autoimmune Diseases
GlobeNewswire  ·  05-21
Fate Therapeutics Announces Presentations at 2026 ASCO and EULAR Annual Meetings Highlighting Off-the-Shelf CAR T-cell Therapy Pipeline for Cancer and Autoimmune Diseases
Fate Therapeutics assumed with a Buy at Jefferies
TIPRANKS  ·  05-20
Fate Therapeutics assumed with a Buy at Jefferies

Introduction

Company Name.
Fate Therapeutics
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma and FT522, to treat lymphoma and autoimmune disorders; and CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.
Issue price:
--